Jaideep Patel, Stephanie Detterline, M.D., Robert Ferguson, M.D.

Slides:



Advertisements
Similar presentations
VTE Prophylaxis in the Hospitalized Patient: Importance and Strategies for Improved Compliance Andrew H. Dombro, M.D. Instructor of Medicine Division of.
Advertisements

Ultrasound Placement of Vena Cava Filters
Pablo M. Bedano M.D. Community Regional Cancer Care.
Optimizing Venous Thromboembolism Prophylaxis using Physician Order Entry: Johns Hopkins Hospital Experience Michael B. Streiff, MD Associate Professor.
Prevention of Pulmonary Embolism in high risk trauma patients
VTE in abdominal-pelvic surgery patients
+ Deep Vein Thrombosis Common, Preventable, and potentially Fatal.
Prophylaxis of Venous Thromboembolism
VTE Prophylaxis Alert to providers and nursing Go live June 24, 2014.
 When untreated, general postsurgical patients risk for Deep Venous Thrombosis (DVT) is 19%-25% (Buckner, et al., 2013).  Post surgical orthopedic patients.
No. 100 Comparison between AMS700TM CX and ColoplastTM Titan inflatable penile prostheses for Peyronie’s disease treatment and remodelling: Clinical outcomes.
Anticoagulation in Acute Ischemic Stroke. TPA: Tissue Plasminogen Activator 1995: NINDS study of TPA administration Design: randomized, double blind placebo-controlled.
Venous thromboembolism: how long to treat?
LIFEBLOOD THE Thrombosis CHARITY Venous thromboembolism – Treatment and secondary prevention Ulcus cruris Chronic PE PE DVT Post-thrombotic syndrome Death.
The Management of Acute Necrotizing Pancreatitis
Medical Patients – VTE Prevention Dale W. Bratzler, DO, MPH Professor and Associate Dean, College of Public Health Professor of Medicine, College of Medicine.
Supervisor: Vs 余垣斌 Presenter: CR 周益聖. INTRODUCTION.
Peri-operative management of anticoagulation Marc Carrier MD, MSc FRCPC Assistant Professor, University of Ottawa Associate Scientist, Ottawa Health Research.
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
Prevention Of Venous Thromboembolism In The Cancer Surgical Patient A K Kakkar Barts and the London School of Medicine and Thrombosis Research Institute,
Hemodialysis Catheter Infection Reduction Kathleen Maloney, RN State University of New York Institute of Technology Department of Nursing Introduction.
DEFINING THE DURATION OF ANTICOAGULATION. HOW LONG TO TREAT A DVT?
Risk assessment for VTE
Prevention of Venous Thromboembolism 8 th ACCP Guidelines Chest 2008.
The Role of Thromboprophylaxis in Elective Spinal Surgery The Role of Thromboprophylaxis in Elective Spinal Surgery VA Elwell, N Koo Ng, D Horner & D Peterson.
Pulmonary Embolism Treatment in Cancer - Is It Different 34th Brazilian Thoracic Conference 6th ALAT Congress 5th Brazil-Portugal Congress Brazilia/DF.
IVC filters what you need to know Sam Chakraverty Consultant Radiologist Ninewells Hospital Dundee, Scotland.
Jomo Osborne Lung-2015 Baltimore, USA July , 2015.
Cost-Consciousness Assignment Ollie Ross DSR 2. Adherence to ACP DVT prophylaxis guidelines Objective: Evaluate adherence to ACP DVT prophylaxis guidelines.
Risk Assessment for VTE. Which of the following best describes you?
Higher Incidence of Venous Thromboembolism (VTE) in the Outpatient versus Inpatient Setting Among Patients with Cancer in the United States Khorana A et.
 Deep Vein Thrombosis Josh Vrona, Hunter Dolan, Erin McCann.
Antithrombotic and Thrombolytic Therapy for Valvular Disease Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
The Risks of Thromboembolism Vs. Recurrent Gastrointestinal Bleeding after Interruption of Systemic Anticoagulation in Hospitalized Inpatients With Gastrointestinal.
Conclusions Results Methods Background Venous thrombo-embolism in patients undergoing neo- adjuvant chemotherapy and surgery for oesophago-gastric cancer.
Prevention of Venous Thromboembolism in Orthopedic Surgery Patients Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy.
Joseph J.Y. Sung, MD et al. Am J Gastroenterol 2010;105. R3 김민경.
Antithrombotic and Thrombolytic Therapy for Valvular Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest.
Dr. Lesbia Adalgisa Rodriguez PGY3-Cook County Loyola Family Medicine Residency Program Venous Thromboembolism Prophylaxis in the Inpatient Setting.
1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.
Anthony Williams, FY2 Jo McCarthy, FY2 Charlotte Davies, FY2
The Diabetic Retinopathy Clinical Research Network
Postoperative Calf Venous Thrombosis: Location, Location, Location
Early Surgery versus Conventional Treatment for Infective Endocarditis
Clinical Professor in Palliative Medicine
Venous Thromboembolism Prophylaxis (VTE)
Update on the Watchman Device CRT 2010 Washington, DC
Decrease The Future Rate Of Dislocation?
By: Dr. Nalaka Gunawansa
The efficacy and safety of oral Rivaroxaban in patients with permanent inferior vena cava filter: a pilot case-control study Lobastov K., Barinov V.,
Insights Using Data from California Richard H. White MD
1: Houston Methodist Neurological Institute, Houston, TX
Concerns with Catheter Directed TPA for the Treatment of PEs
Assessing the uptake of national initiatives
Columbia University College of Physicians and Surgeons
Dr.H.Chandrashekar, Dr.A.Chaudhuri, Dr. A. Douglas, Dr. D. Lowdon
Evaluation of Four Factor Prothrombin Complex Concentrate
Prognosis of younger patients in non-small cell lung cancer
Prevention of Venous Thromboembolism in Orthopedic Surgery Patients
Optional IVC Filters: Indications for Placement and Retrieval
Thromboprophylaxis during labour and delivery
The Utilization of Sequential Compression Devices Among Pregnant Women
Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.
NOACS: Emerging data in ACS/IHD
Section F: Clinical guidelines
Extraordinary Cases of VTE Prevention in Patients With Cancer
Who, where, why, and the data behind it.
NOAC Studies in VTE AF Studies Superior Outcomes.
PPI prophylaxis for GI bleeding in ICU
Varicose Veins and IVC Filter Registries
Presentation transcript:

Inferior Vena Cava Filter Placement Patterns: Our experience and a review of the literature Jaideep Patel, Stephanie Detterline, M.D., Robert Ferguson, M.D. ACP Internal Medicine 2010 – Toronto, April 24th, 2010

Available data  case reports, with few animal or in vitro studies, reviews, and prospective studies Only 1 RTC available  Decousus et al Pts with DVT (w/ or w/o PE) randomized to receive  Filter vs no filter Also all patients were anticoagulated for 3 months. filter group had a significantly lower incidence of PE during the first 12 days than the non-filter group. May benefit patients with high risk PE  overlooked that IVC filters have their own inherent risks and complications and may not be the best management strategy for every patient

Concerning because it has great implications for both patient safety and proper utilization of resources.

National Hospital Discharge Survey (1979-1999) Numbers begin to increase sharply in 1988 Increasing use of filters, with development in filter technology (Nonthromogenic, High filtering efficiency , Retrievable) ----------- large and small emboli (without impedance of flow) Secure fixation within the vena cava Rapid percutaneous insertion Smaller caliber Amenable to repositioning Simple release mechanism MRI compatible Low cost Retrievable Stein PD, Kayali F, Olson RE. Twenty-one-year trends in the use of inferior vena cava filters. Arch Intern Med 2004; 164:1541-1545.

Objective Review our institutional practices regarding IVC filter placement and compare this to available published guidelines to better understand our compliance with the available evidence. Want to ensure we are appropriately placing IVC filters because according to the NEJM study, having an IVC filter shows no effect on survival WANTED TO ASSES OUR USE of IVC FILTERS IN OUR INSTITUTION

Methods Retrospective review of patients undergoing temporary or permanent IVC filter implantation from 2001 to 2009. Demographics, clinical presentation, indications for placement according to ACCP (2008) and extended guidelines, filter type, and hypercoagulable risk factors were collected for each case.

Methods In each case, indications for IVC filter placement were determined to be either: Indicated by absolute guidelines (G) Indicated by relative guidelines (EG) Met neither criteria for placement (NG) Also on a case by case basis, IVC filter placement was determined to be

Absolute Guidelines for IVC Filter Placement - ACCP(2008) Proven VTE with contraindications for anticoagulation Proven VTE with complications of anticoagulation treatment Recurrent VTE despite anticoagulation treatment (failure of anticoagulation) Adapted from Chest 1,2

Relative extended guideline indications for IVF Filter placement Recent VTE and operative procedure requiring prolonged withholding of anticoagulation Patients with DVT and limited cardiopulmonary reserve or COPD Patients with DVT who have cancer, burns or are pregnant Large/free floating iliofemoral thrombus in high risk patient Following thrombectomy/embelectomy/thrombolysis of a DVT Propagating iliofemoral thrombus while anticoagulated High risk surgical patients with anticoagulation contraindication Major abdominal surgery within the past 2 days Gastrointestinal or genitourinary bleeding within the past 14 days Chronic PE in patient with pulmonary hypertension and cor pulmonale Malignant hypertension Infective endocarditis Adapted from Blood , J Vasc Interv Radio , Am J Med  Unfortunately, the ACCP Guidelines, are not clear in the definitions of what a contraindications or complications are, and for that reason  many who argue there are other compelling reasons for filter placement  Other than the ABSOLUTE recommended guidelines, there is also a list of RELATIVE guidelines  Often mentioned, but not widely agreed upon and include - read off two of them keep in mind NOT absolute  once again NOT ABSOLUTE

Total Filters Placed During Study Period Results: Total Filters Placed During Study Period Overall INCRESING trend in total number of filters placed * Data collected until September 2009

Results Fully 50% of our filters were guideline indicated, and the remaining ½ were either EG or NG Of our 50% that followed absolute guidelines for placement , 50% were placed in patients who had an acute VTE and a contraindication for IVC placement

Contraindications to Anticoagualtion Therapy If we break down the contraindications to IVC filter placement in our study Major risk of falling n=40 33.3% Overt GI bleed/guiac positive stools n=24 20.0% 1/3 of these filters were not placed due to patient having a high risk of fall This was followed closely by patients being heme positive

Complications of Anticoagulation Therapy 97% of patients encountered bleeding as their complication to AC therapy, and hence received a filter

Results 27% of our patients had filters placed according to the Relative Guidelines for IVC Filter placement

Relative Indications for Placement In regards to RELATIVE Guidelines, 27% 71% of our patients had an IVC filter placed due to the fact that they were undergoing an operative procedure which required holding of AC Attribute it to Union being a surgical center, with a stellar orthopedic unit

Conclusions 50% Indicated by absolute guidelines (G) 27% Indicated by relative guidelines (EG) 23% Met neither criteria for placement (NG) In summary, 50% of our patients had IVC filters placed according to current ACCP guideline What was concerning to us though was the 23% of patients who met neither criteria for IVC filter placement Concerning from a safety standpoint, given that IVC filters have shown no effect on survival

Conclusion Our practices our comparable Limitations Physician understanding Unclear recommendations/guidelines Poor dictation Patient follow-up Kalva (2006) – study from Mass General – 28% prophylaxis; 72% G Moris (2004) – study from U. of Vermont - 48% prophylaxis; 52% G Dorvish et all (2005) – 27% prophylaxis; 73% G – Israeli multicenter study Hammond et al (2008) – 57% G; 37% R; 6% prophylaxis – UK multicenter study Ivette (2007) – 13.6% Prophylaxis; 71% G; 12.2% R – Chilean study Singh et al (2009) - 65% WG, 35% OOG - US Given this data, we seem to fall within the range at which other hospitals are placing IVC filters outside of the accepted guidelines However, we feel a great need for more research on the proper indications, and greater attention to enforce those already in existence Future studies Patient follow-up